FLT3 Inhibitors in Acute Myeloid Leukemia: Choosing the Best when the Optimal Does Not Exist.

Abstract

Despite significant advances in deciphering the molecular and cytogenetic pathways governing acute myeloid leukemia, improvements in treatment strategies and clinical outcomes have been limited. The discovery of FLT3 pathway and its potential role in leukemogenesis has generated excitement in the field and has provided a potential target for drug… (More)
DOI: 10.1002/ajh.25027

Cite this paper

@article{Assi2017FLT3II, title={FLT3 Inhibitors in Acute Myeloid Leukemia: Choosing the Best when the Optimal Does Not Exist.}, author={Rita Assi and Farhad Ravandi}, journal={American journal of hematology}, year={2017} }